JP2007504882A - 使い捨て電気包帯 - Google Patents
使い捨て電気包帯 Download PDFInfo
- Publication number
- JP2007504882A JP2007504882A JP2006526003A JP2006526003A JP2007504882A JP 2007504882 A JP2007504882 A JP 2007504882A JP 2006526003 A JP2006526003 A JP 2006526003A JP 2006526003 A JP2006526003 A JP 2006526003A JP 2007504882 A JP2007504882 A JP 2007504882A
- Authority
- JP
- Japan
- Prior art keywords
- electrode
- wound
- power source
- treatment
- patch
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000027418 Wounds and injury Diseases 0.000 claims abstract description 181
- 206010052428 Wound Diseases 0.000 claims abstract description 172
- 238000011282 treatment Methods 0.000 claims abstract description 114
- 239000013543 active substance Substances 0.000 claims abstract description 47
- 239000000758 substrate Substances 0.000 claims abstract description 30
- 238000000034 method Methods 0.000 claims abstract description 27
- 238000002560 therapeutic procedure Methods 0.000 claims abstract description 17
- 238000009736 wetting Methods 0.000 claims abstract description 15
- 239000000203 mixture Substances 0.000 claims abstract description 14
- 239000000017 hydrogel Substances 0.000 claims description 47
- 239000000463 material Substances 0.000 claims description 27
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 26
- 229910052725 zinc Inorganic materials 0.000 claims description 24
- 239000011701 zinc Substances 0.000 claims description 24
- 230000029663 wound healing Effects 0.000 claims description 22
- 230000002093 peripheral effect Effects 0.000 claims description 20
- 208000014674 injury Diseases 0.000 claims description 14
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 claims description 13
- 239000003814 drug Substances 0.000 claims description 13
- 229940079593 drug Drugs 0.000 claims description 13
- 239000007800 oxidant agent Substances 0.000 claims description 13
- 230000006378 damage Effects 0.000 claims description 12
- 239000000499 gel Substances 0.000 claims description 12
- 210000001519 tissue Anatomy 0.000 claims description 12
- 239000000853 adhesive Substances 0.000 claims description 11
- 230000001070 adhesive effect Effects 0.000 claims description 11
- 239000012530 fluid Substances 0.000 claims description 11
- 238000004381 surface treatment Methods 0.000 claims description 11
- 239000004020 conductor Substances 0.000 claims description 8
- 230000008878 coupling Effects 0.000 claims description 8
- 238000010168 coupling process Methods 0.000 claims description 8
- 238000005859 coupling reaction Methods 0.000 claims description 8
- 239000003102 growth factor Substances 0.000 claims description 8
- 210000003205 muscle Anatomy 0.000 claims description 8
- 239000003792 electrolyte Substances 0.000 claims description 7
- 238000009472 formulation Methods 0.000 claims description 7
- 239000002195 soluble material Substances 0.000 claims description 7
- 208000025865 Ulcer Diseases 0.000 claims description 6
- 230000000845 anti-microbial effect Effects 0.000 claims description 6
- 239000006071 cream Substances 0.000 claims description 6
- 230000006870 function Effects 0.000 claims description 6
- 239000006210 lotion Substances 0.000 claims description 6
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims description 6
- 239000000126 substance Substances 0.000 claims description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 5
- 239000002250 absorbent Substances 0.000 claims description 5
- 230000002745 absorbent Effects 0.000 claims description 5
- 229940121375 antifungal agent Drugs 0.000 claims description 5
- 230000000694 effects Effects 0.000 claims description 5
- 238000011065 in-situ storage Methods 0.000 claims description 5
- 229910052709 silver Inorganic materials 0.000 claims description 5
- 239000004332 silver Substances 0.000 claims description 5
- 231100000397 ulcer Toxicity 0.000 claims description 5
- 206010056340 Diabetic ulcer Diseases 0.000 claims description 4
- 208000035874 Excoriation Diseases 0.000 claims description 4
- 208000034693 Laceration Diseases 0.000 claims description 4
- 208000004210 Pressure Ulcer Diseases 0.000 claims description 4
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 claims description 4
- 206010042220 Stress ulcer Diseases 0.000 claims description 4
- 206010042496 Sunburn Diseases 0.000 claims description 4
- 208000002847 Surgical Wound Diseases 0.000 claims description 4
- 230000017531 blood circulation Effects 0.000 claims description 4
- 208000000718 duodenal ulcer Diseases 0.000 claims description 4
- 230000033001 locomotion Effects 0.000 claims description 4
- NUJOXMJBOLGQSY-UHFFFAOYSA-N manganese dioxide Chemical compound O=[Mn]=O NUJOXMJBOLGQSY-UHFFFAOYSA-N 0.000 claims description 4
- 230000007383 nerve stimulation Effects 0.000 claims description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims description 4
- 231100000241 scar Toxicity 0.000 claims description 4
- 230000001953 sensory effect Effects 0.000 claims description 4
- 230000002195 synergetic effect Effects 0.000 claims description 4
- 229920003169 water-soluble polymer Polymers 0.000 claims description 4
- 208000032544 Cicatrix Diseases 0.000 claims description 3
- 208000003790 Foot Ulcer Diseases 0.000 claims description 3
- 230000018044 dehydration Effects 0.000 claims description 3
- 238000006297 dehydration reaction Methods 0.000 claims description 3
- 229910002804 graphite Inorganic materials 0.000 claims description 3
- 239000010439 graphite Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000003589 local anesthetic agent Substances 0.000 claims description 3
- 229960005015 local anesthetics Drugs 0.000 claims description 3
- 210000000578 peripheral nerve Anatomy 0.000 claims description 3
- 230000008929 regeneration Effects 0.000 claims description 3
- 238000011069 regeneration method Methods 0.000 claims description 3
- 230000037390 scarring Effects 0.000 claims description 3
- 230000037387 scars Effects 0.000 claims description 3
- 230000008733 trauma Effects 0.000 claims description 3
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 claims description 2
- 229910021607 Silver chloride Inorganic materials 0.000 claims description 2
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 claims description 2
- 229910052782 aluminium Inorganic materials 0.000 claims description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
- 239000003429 antifungal agent Substances 0.000 claims description 2
- 239000004599 antimicrobial Substances 0.000 claims description 2
- 239000003443 antiviral agent Substances 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 229910052802 copper Inorganic materials 0.000 claims description 2
- 239000010949 copper Substances 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052737 gold Inorganic materials 0.000 claims description 2
- 239000010931 gold Substances 0.000 claims description 2
- 235000008216 herbs Nutrition 0.000 claims description 2
- 244000005700 microbiome Species 0.000 claims description 2
- 230000001338 necrotic effect Effects 0.000 claims description 2
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 229910052697 platinum Inorganic materials 0.000 claims description 2
- 230000008439 repair process Effects 0.000 claims description 2
- 230000000241 respiratory effect Effects 0.000 claims description 2
- HKZLPVFGJNLROG-UHFFFAOYSA-M silver monochloride Chemical compound [Cl-].[Ag+] HKZLPVFGJNLROG-UHFFFAOYSA-M 0.000 claims description 2
- 230000008591 skin barrier function Effects 0.000 claims description 2
- 229910001220 stainless steel Inorganic materials 0.000 claims description 2
- 239000010935 stainless steel Substances 0.000 claims description 2
- 230000008467 tissue growth Effects 0.000 claims description 2
- 230000017423 tissue regeneration Effects 0.000 claims description 2
- 239000010936 titanium Substances 0.000 claims description 2
- 229910052719 titanium Inorganic materials 0.000 claims description 2
- 230000004936 stimulating effect Effects 0.000 claims 2
- 208000004221 Multiple Trauma Diseases 0.000 claims 1
- 206010053692 Wound complication Diseases 0.000 claims 1
- 239000012190 activator Substances 0.000 claims 1
- 230000000638 stimulation Effects 0.000 abstract description 37
- 238000007639 printing Methods 0.000 abstract description 7
- 210000004027 cell Anatomy 0.000 description 35
- 210000003491 skin Anatomy 0.000 description 23
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 15
- 239000004480 active ingredient Substances 0.000 description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 10
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- -1 for example Substances 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229910052751 metal Inorganic materials 0.000 description 7
- 239000002184 metal Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000008901 benefit Effects 0.000 description 6
- 150000003839 salts Chemical class 0.000 description 6
- 239000003349 gelling agent Substances 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 230000001590 oxidative effect Effects 0.000 description 5
- 229920000642 polymer Polymers 0.000 description 5
- 229920002125 Sokalan® Polymers 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 230000005856 abnormality Effects 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 229960003276 erythromycin Drugs 0.000 description 4
- 230000035876 healing Effects 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- BHHYHSUAOQUXJK-UHFFFAOYSA-L zinc fluoride Chemical compound F[Zn]F BHHYHSUAOQUXJK-UHFFFAOYSA-L 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 230000000843 anti-fungal effect Effects 0.000 description 3
- 230000002146 bilateral effect Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- AEUTYOVWOVBAKS-UWVGGRQHSA-N ethambutol Chemical compound CC[C@@H](CO)NCCN[C@@H](CC)CO AEUTYOVWOVBAKS-UWVGGRQHSA-N 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 239000004584 polyacrylic acid Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 238000007634 remodeling Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 108010065839 Capreomycin Proteins 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 102000009024 Epidermal Growth Factor Human genes 0.000 description 2
- 101800003838 Epidermal growth factor Proteins 0.000 description 2
- 229920003148 Eudragit® E polymer Polymers 0.000 description 2
- 229920003136 Eudragit® L polymer Polymers 0.000 description 2
- 229920003137 Eudragit® S polymer Polymers 0.000 description 2
- 229920003134 Eudragit® polymer Polymers 0.000 description 2
- 108050007372 Fibroblast Growth Factor Proteins 0.000 description 2
- 102000018233 Fibroblast Growth Factor Human genes 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 2
- BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 2
- MITFXPHMIHQXPI-UHFFFAOYSA-N Oraflex Chemical compound N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 2
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 2
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 206010039509 Scab Diseases 0.000 description 2
- 206010072170 Skin wound Diseases 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000003110 anti-inflammatory effect Effects 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002301 cellulose acetate Polymers 0.000 description 2
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 239000011231 conductive filler Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 229960003722 doxycycline Drugs 0.000 description 2
- 238000005370 electroosmosis Methods 0.000 description 2
- 229940116977 epidermal growth factor Drugs 0.000 description 2
- 239000004744 fabric Substances 0.000 description 2
- 229940126864 fibroblast growth factor Drugs 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 150000002739 metals Chemical class 0.000 description 2
- 229960002509 miconazole Drugs 0.000 description 2
- 230000017074 necrotic cell death Effects 0.000 description 2
- 229910000480 nickel oxide Inorganic materials 0.000 description 2
- 239000012811 non-conductive material Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- GNRSAWUEBMWBQH-UHFFFAOYSA-N oxonickel Chemical compound [Ni]=O GNRSAWUEBMWBQH-UHFFFAOYSA-N 0.000 description 2
- 239000000123 paper Substances 0.000 description 2
- XDRYMKDFEDOLFX-UHFFFAOYSA-N pentamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCOC1=CC=C(C(N)=N)C=C1 XDRYMKDFEDOLFX-UHFFFAOYSA-N 0.000 description 2
- 229960004448 pentamidine Drugs 0.000 description 2
- 229920003023 plastic Polymers 0.000 description 2
- 239000004033 plastic Substances 0.000 description 2
- 229920000058 polyacrylate Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 2
- 229940069328 povidone Drugs 0.000 description 2
- 230000000541 pulsatile effect Effects 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 2
- VNDYJBBGRKZCSX-UHFFFAOYSA-L zinc bromide Chemical compound Br[Zn]Br VNDYJBBGRKZCSX-UHFFFAOYSA-L 0.000 description 2
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 2
- CIDUJQMULVCIBT-CWCLBWQUSA-N (2R,3R,4R,5R)-2-[(1S,2S,3S,4S,6R)-4-amino-3-[[(2S,3R)-3-amino-6-(aminomethyl)-3,4-dihydro-2H-pyran-2-yl]oxy]-6-(ethylamino)-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound CCN[C@@H]1C[C@H](N)[C@H](O[C@H]2OC(CN)=CC[C@H]2N)[C@H](O)[C@H]1O[C@H]1OC[C@](C)(O)[C@H](NC)[C@H]1O CIDUJQMULVCIBT-CWCLBWQUSA-N 0.000 description 1
- RJMIEHBSYVWVIN-LLVKDONJSA-N (2r)-2-[4-(3-oxo-1h-isoindol-2-yl)phenyl]propanoic acid Chemical compound C1=CC([C@H](C(O)=O)C)=CC=C1N1C(=O)C2=CC=CC=C2C1 RJMIEHBSYVWVIN-LLVKDONJSA-N 0.000 description 1
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 1
- RDJGLLICXDHJDY-NSHDSACASA-N (2s)-2-(3-phenoxyphenyl)propanoic acid Chemical compound OC(=O)[C@@H](C)C1=CC=CC(OC=2C=CC=CC=2)=C1 RDJGLLICXDHJDY-NSHDSACASA-N 0.000 description 1
- MDKGKXOCJGEUJW-VIFPVBQESA-N (2s)-2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C(=O)C1=CC=CS1 MDKGKXOCJGEUJW-VIFPVBQESA-N 0.000 description 1
- VCOPTHOUUNAYKQ-WBTCAYNUSA-N (3s)-3,6-diamino-n-[[(2s,5s,8e,11s,15s)-15-amino-11-[(6r)-2-amino-1,4,5,6-tetrahydropyrimidin-6-yl]-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;(3s)-3,6-diamino-n-[[(2s,5s,8 Chemical compound N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1.N1C(=O)\C(=C/NC(N)=O)NC(=O)[C@H](CNC(=O)C[C@@H](N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1[C@@H]1NC(N)=NCC1 VCOPTHOUUNAYKQ-WBTCAYNUSA-N 0.000 description 1
- XIYOPDCBBDCGOE-IWVLMIASSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide Chemical compound C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O XIYOPDCBBDCGOE-IWVLMIASSA-N 0.000 description 1
- VXPSARQTYDZXAO-CCHMMTNSSA-N (4s,4ar,5s,5ar,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methylidene-3,12-dioxo-4,4a,5,5a-tetrahydrotetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C=C1C2=CC=CC(O)=C2C(O)=C2[C@@H]1[C@H](O)[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O VXPSARQTYDZXAO-CCHMMTNSSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OAAZUWWNSYWWHG-UHFFFAOYSA-N 1-phenoxypropan-1-ol Chemical compound CCC(O)OC1=CC=CC=C1 OAAZUWWNSYWWHG-UHFFFAOYSA-N 0.000 description 1
- IBLKWZIFZMJLFL-UHFFFAOYSA-N 1-phenoxypropan-2-ol Chemical compound CC(O)COC1=CC=CC=C1 IBLKWZIFZMJLFL-UHFFFAOYSA-N 0.000 description 1
- RRTWWCUPXVRJFP-UHFFFAOYSA-N 2-(3-ethenyl-2-oxopyrrolidin-1-yl)acetic acid Chemical compound OC(=O)CN1CCC(C=C)C1=O RRTWWCUPXVRJFP-UHFFFAOYSA-N 0.000 description 1
- TYCOFFBAZNSQOJ-UHFFFAOYSA-N 2-[4-(3-fluorophenyl)phenyl]propanoic acid Chemical compound C1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC(F)=C1 TYCOFFBAZNSQOJ-UHFFFAOYSA-N 0.000 description 1
- JVTIXNMXDLQEJE-UHFFFAOYSA-N 2-decanoyloxypropyl decanoate 2-octanoyloxypropyl octanoate Chemical compound C(CCCCCCC)(=O)OCC(C)OC(CCCCCCC)=O.C(=O)(CCCCCCCCC)OCC(C)OC(=O)CCCCCCCCC JVTIXNMXDLQEJE-UHFFFAOYSA-N 0.000 description 1
- OGQYJDHTHFAPRN-UHFFFAOYSA-N 2-fluoro-6-(trifluoromethyl)benzonitrile Chemical compound FC1=CC=CC(C(F)(F)F)=C1C#N OGQYJDHTHFAPRN-UHFFFAOYSA-N 0.000 description 1
- WLAMNBDJUVNPJU-UHFFFAOYSA-N 2-methylbutyric acid Chemical compound CCC(C)C(O)=O WLAMNBDJUVNPJU-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- ILYSAKHOYBPSPC-UHFFFAOYSA-N 2-phenylbenzoic acid Chemical class OC(=O)C1=CC=CC=C1C1=CC=CC=C1 ILYSAKHOYBPSPC-UHFFFAOYSA-N 0.000 description 1
- TUATYNXRYJTQTQ-BVRBKCERSA-N 3,6-diamino-n-[[(2s,5s,8z,11s,15s)-15-amino-11-(2-amino-1,4,5,6-tetrahydropyrimidin-6-yl)-8-[(carbamoylamino)methylidene]-2-(hydroxymethyl)-3,6,9,12,16-pentaoxo-1,4,7,10,13-pentazacyclohexadec-5-yl]methyl]hexanamide;3,6-diamino-n-[[(2s,5s,8z,11s,15s)-15-a Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC(=O)[C@H](C)NC(=O)[C@@H](N)CNC(=O)[C@@H]1C1NC(=N)NCC1.N1C(=O)\C(=C\NC(N)=O)NC(=O)[C@H](CNC(=O)CC(N)CCCN)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CNC(=O)[C@@H]1C1NC(=N)NCC1 TUATYNXRYJTQTQ-BVRBKCERSA-N 0.000 description 1
- WTJXVDPDEQKTCV-UHFFFAOYSA-N 4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide;hydron;chloride Chemical compound Cl.C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2C1CC1C(N(C)C)C(=O)C(C(N)=O)=C(O)C1(O)C2=O WTJXVDPDEQKTCV-UHFFFAOYSA-N 0.000 description 1
- YWMSSKBMOFPBDM-UHFFFAOYSA-N 4-carbamoylbenzenesulfonyl chloride Chemical compound NC(=O)C1=CC=C(S(Cl)(=O)=O)C=C1 YWMSSKBMOFPBDM-UHFFFAOYSA-N 0.000 description 1
- BSYNRYMUTXBXSQ-FOQJRBATSA-N 59096-14-9 Chemical compound CC(=O)OC1=CC=CC=C1[14C](O)=O BSYNRYMUTXBXSQ-FOQJRBATSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 229910002014 Aerosil® 130 Inorganic materials 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- 240000002234 Allium sativum Species 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 240000000662 Anethum graveolens Species 0.000 description 1
- 241000086254 Arnica montana Species 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- 229920000049 Carbon (fiber) Polymers 0.000 description 1
- 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 1
- WJLVQTJZDCGNJN-UHFFFAOYSA-N Chlorhexidine hydrochloride Chemical compound Cl.Cl.C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 WJLVQTJZDCGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 240000007154 Coffea arabica Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- YAVZHCFFUATPRK-YZPBMOCRSA-N Erythromycin stearate Chemical compound CCCCCCCCCCCCCCCCCC(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 YAVZHCFFUATPRK-YZPBMOCRSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- VTUSIVBDOCDNHS-UHFFFAOYSA-N Etidocaine Chemical compound CCCN(CC)C(CC)C(=O)NC1=C(C)C=CC=C1C VTUSIVBDOCDNHS-UHFFFAOYSA-N 0.000 description 1
- 229920003151 Eudragit® RL polymer Polymers 0.000 description 1
- 229920003152 Eudragit® RS polymer Polymers 0.000 description 1
- 229930182566 Gentamicin Natural products 0.000 description 1
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- DKLKMKYDWHYZTD-UHFFFAOYSA-N Hexylcaine Chemical compound C=1C=CC=CC=1C(=O)OC(C)CNC1CCCCC1 DKLKMKYDWHYZTD-UHFFFAOYSA-N 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 1
- 102000006992 Interferon-alpha Human genes 0.000 description 1
- 108010047761 Interferon-alpha Proteins 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 108090000467 Interferon-beta Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
- 235000013628 Lantana involucrata Nutrition 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- ROAIXOJGRFKICW-UHFFFAOYSA-N Methenamine hippurate Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)CNC(=O)C1=CC=CC=C1 ROAIXOJGRFKICW-UHFFFAOYSA-N 0.000 description 1
- 229920003091 Methocel™ Polymers 0.000 description 1
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 1
- 235000006677 Monarda citriodora ssp. austromontana Nutrition 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
- CMWTZPSULFXXJA-UHFFFAOYSA-N Naproxen Natural products C1=C(C(C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 240000007673 Origanum vulgare Species 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
- 229920005439 Perspex® Polymers 0.000 description 1
- 239000004264 Petrolatum Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 244000134552 Plantago ovata Species 0.000 description 1
- 235000003421 Plantago ovata Nutrition 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- TVQZAMVBTVNYLA-UHFFFAOYSA-N Pranoprofen Chemical compound C1=CC=C2CC3=CC(C(C(O)=O)C)=CC=C3OC2=N1 TVQZAMVBTVNYLA-UHFFFAOYSA-N 0.000 description 1
- 241000241413 Propolis Species 0.000 description 1
- 239000009223 Psyllium Substances 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 240000002299 Symphytum officinale Species 0.000 description 1
- 235000005865 Symphytum officinale Nutrition 0.000 description 1
- 208000003217 Tetany Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- XEFQLINVKFYRCS-UHFFFAOYSA-N Triclosan Chemical compound OC1=CC(Cl)=CC=C1OC1=CC=C(Cl)C=C1Cl XEFQLINVKFYRCS-UHFFFAOYSA-N 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 238000001467 acupuncture Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 229960004821 amikacin Drugs 0.000 description 1
- LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 1
- 229960001656 amikacin sulfate Drugs 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 229940111133 antiinflammatory and antirheumatic drug oxicams Drugs 0.000 description 1
- 229940111131 antiinflammatory and antirheumatic product propionic acid derivative Drugs 0.000 description 1
- 239000000305 astragalus gummifer gum Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 208000020538 atrophic muscular disease Diseases 0.000 description 1
- 229960000892 attapulgite Drugs 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000003651 basophil Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229960005430 benoxaprofen Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 238000005842 biochemical reaction Methods 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- IJTPQQVCKPZIMV-UHFFFAOYSA-N bucloxic acid Chemical compound ClC1=CC(C(=O)CCC(=O)O)=CC=C1C1CCCCC1 IJTPQQVCKPZIMV-UHFFFAOYSA-N 0.000 description 1
- 229950005608 bucloxic acid Drugs 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- BDOSMKKIYDKNTQ-UHFFFAOYSA-N cadmium atom Chemical compound [Cd] BDOSMKKIYDKNTQ-UHFFFAOYSA-N 0.000 description 1
- 229910001622 calcium bromide Inorganic materials 0.000 description 1
- WGEFECGEFUFIQW-UHFFFAOYSA-L calcium dibromide Chemical compound [Ca+2].[Br-].[Br-] WGEFECGEFUFIQW-UHFFFAOYSA-L 0.000 description 1
- 229960004602 capreomycin Drugs 0.000 description 1
- 229960002968 capreomycin sulfate Drugs 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000004917 carbon fiber Substances 0.000 description 1
- 229920003123 carboxymethyl cellulose sodium Polymers 0.000 description 1
- 229940063834 carboxymethylcellulose sodium Drugs 0.000 description 1
- 239000011111 cardboard Substances 0.000 description 1
- 229960003184 carprofen Drugs 0.000 description 1
- IVUMCTKHWDRRMH-UHFFFAOYSA-N carprofen Chemical compound C1=CC(Cl)=C[C]2C3=CC=C(C(C(O)=O)C)C=C3N=C21 IVUMCTKHWDRRMH-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- XMEVHPAGJVLHIG-FMZCEJRJSA-N chembl454950 Chemical compound [Cl-].C1=CC=C2[C@](O)(C)[C@H]3C[C@H]4[C@H]([NH+](C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O XMEVHPAGJVLHIG-FMZCEJRJSA-N 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960003260 chlorhexidine Drugs 0.000 description 1
- 229960003333 chlorhexidine gluconate Drugs 0.000 description 1
- YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 1
- 229960004504 chlorhexidine hydrochloride Drugs 0.000 description 1
- 229960002023 chloroprocaine Drugs 0.000 description 1
- VDANGULDQQJODZ-UHFFFAOYSA-N chloroprocaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1Cl VDANGULDQQJODZ-UHFFFAOYSA-N 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 229960003185 chlortetracycline hydrochloride Drugs 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 229960003405 ciprofloxacin Drugs 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- 229960001200 clindamycin hydrochloride Drugs 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 229920006026 co-polymeric resin Polymers 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 235000016213 coffee Nutrition 0.000 description 1
- 235000013353 coffee beverage Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960000633 dextran sulfate Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- LEQISTNVGGEONS-UHFFFAOYSA-L dizinc bromide chloride Chemical compound [Br-].[Zn+2].[Cl-].[Zn+2] LEQISTNVGGEONS-UHFFFAOYSA-L 0.000 description 1
- 230000005684 electric field Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 230000008472 epithelial growth Effects 0.000 description 1
- 229960004142 erythromycin stearate Drugs 0.000 description 1
- 229960000285 ethambutol Drugs 0.000 description 1
- 229960001618 ethambutol hydrochloride Drugs 0.000 description 1
- 229960003976 etidocaine Drugs 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960001395 fenbufen Drugs 0.000 description 1
- ZPAKPRAICRBAOD-UHFFFAOYSA-N fenbufen Chemical compound C1=CC(C(=O)CCC(=O)O)=CC=C1C1=CC=CC=C1 ZPAKPRAICRBAOD-UHFFFAOYSA-N 0.000 description 1
- 229960001419 fenoprofen Drugs 0.000 description 1
- 229950001284 fluprofen Drugs 0.000 description 1
- 229960002390 flurbiprofen Drugs 0.000 description 1
- SYTBZMRGLBWNTM-UHFFFAOYSA-N flurbiprofen Chemical compound FC1=CC(C(C(O)=O)C)=CC=C1C1=CC=CC=C1 SYTBZMRGLBWNTM-UHFFFAOYSA-N 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 235000004611 garlic Nutrition 0.000 description 1
- 229960002518 gentamicin Drugs 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 235000009569 green tea Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- UXNFIJPHRQEWRQ-UHFFFAOYSA-N hexamethylenetetramine mandelate salt Chemical compound C1N(C2)CN3CN1CN2C3.OC(=O)C(O)C1=CC=CC=C1 UXNFIJPHRQEWRQ-UHFFFAOYSA-N 0.000 description 1
- 229960001915 hexamidine Drugs 0.000 description 1
- OQLKNTOKMBVBKV-UHFFFAOYSA-N hexamidine Chemical compound C1=CC(C(=N)N)=CC=C1OCCCCCCOC1=CC=C(C(N)=N)C=C1 OQLKNTOKMBVBKV-UHFFFAOYSA-N 0.000 description 1
- 229960005388 hexylcaine Drugs 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 229920001600 hydrophobic polymer Polymers 0.000 description 1
- 229920013821 hydroxy alkyl cellulose Polymers 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 229940071676 hydroxypropylcellulose Drugs 0.000 description 1
- WQYVRQLZKVEZGA-UHFFFAOYSA-N hypochlorite Inorganic materials Cl[O-] WQYVRQLZKVEZGA-UHFFFAOYSA-N 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- CFUQBFQTFMOZBK-QUCCMNQESA-N ibazocine Chemical compound C12=CC(O)=CC=C2C[C@H]2N(CC=C(C)C)CC[C@]1(C)C2(C)C CFUQBFQTFMOZBK-QUCCMNQESA-N 0.000 description 1
- 229960001680 ibuprofen Drugs 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 229960004187 indoprofen Drugs 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- OOYGSFOGFJDDHP-KMCOLRRFSA-N kanamycin A sulfate Chemical compound OS(O)(=O)=O.O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N OOYGSFOGFJDDHP-KMCOLRRFSA-N 0.000 description 1
- 229960002064 kanamycin sulfate Drugs 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 229960003299 ketamine Drugs 0.000 description 1
- DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 description 1
- 229960000991 ketoprofen Drugs 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 229910000464 lead oxide Inorganic materials 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000007769 metal material Substances 0.000 description 1
- 125000005395 methacrylic acid group Chemical group 0.000 description 1
- 229940042016 methacycline Drugs 0.000 description 1
- 229960003900 methenamine hippurate Drugs 0.000 description 1
- 229960002786 methenamine mandelate Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 229960000282 metronidazole Drugs 0.000 description 1
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 description 1
- FPTPAIQTXYFGJC-UHFFFAOYSA-N metronidazole hydrochloride Chemical compound Cl.CC1=NC=C([N+]([O-])=O)N1CCO FPTPAIQTXYFGJC-UHFFFAOYSA-N 0.000 description 1
- 229960002395 metronidazole hydrochloride Drugs 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 229960002421 minocycline hydrochloride Drugs 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229960002009 naproxen Drugs 0.000 description 1
- CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical compound C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229940053050 neomycin sulfate Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 239000004745 nonwoven fabric Substances 0.000 description 1
- 229960001180 norfloxacin Drugs 0.000 description 1
- OGJPXUAPXNRGGI-UHFFFAOYSA-N norfloxacin Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC(F)=C1N1CCNCC1 OGJPXUAPXNRGGI-UHFFFAOYSA-N 0.000 description 1
- 229960000988 nystatin Drugs 0.000 description 1
- VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 1
- 238000007645 offset printing Methods 0.000 description 1
- 229960002739 oxaprozin Drugs 0.000 description 1
- OFPXSFXSNFPTHF-UHFFFAOYSA-N oxaprozin Chemical compound O1C(CCC(=O)O)=NC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 OFPXSFXSNFPTHF-UHFFFAOYSA-N 0.000 description 1
- YEXPOXQUZXUXJW-UHFFFAOYSA-N oxolead Chemical compound [Pb]=O YEXPOXQUZXUXJW-UHFFFAOYSA-N 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 229960004368 oxytetracycline hydrochloride Drugs 0.000 description 1
- 229910052625 palygorskite Inorganic materials 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- 229960005065 paromomycin sulfate Drugs 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-M perchlorate Inorganic materials [O-]Cl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-M 0.000 description 1
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 229940066842 petrolatum Drugs 0.000 description 1
- 235000019271 petrolatum Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 229940106026 phenoxyisopropanol Drugs 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 229950001046 piroctone Drugs 0.000 description 1
- BTSZTGGZJQFALU-UHFFFAOYSA-N piroctone olamine Chemical compound NCCO.CC(C)(C)CC(C)CC1=CC(C)=CC(=O)N1O BTSZTGGZJQFALU-UHFFFAOYSA-N 0.000 description 1
- 229920000191 poly(N-vinyl pyrrolidone) Polymers 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 235000011056 potassium acetate Nutrition 0.000 description 1
- 229960001896 pramocaine Drugs 0.000 description 1
- DQKXQSGTHWVTAD-UHFFFAOYSA-N pramocaine Chemical compound C1=CC(OCCCC)=CC=C1OCCCN1CCOCC1 DQKXQSGTHWVTAD-UHFFFAOYSA-N 0.000 description 1
- 229960003101 pranoprofen Drugs 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 229960004919 procaine Drugs 0.000 description 1
- MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 150000005599 propionic acid derivatives Chemical class 0.000 description 1
- 229940069949 propolis Drugs 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940070687 psyllium Drugs 0.000 description 1
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 230000027756 respiratory electron transport chain Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000036573 scar formation Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 230000008470 skin growth Effects 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 229910000679 solder Inorganic materials 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000002294 steroidal antiinflammatory agent Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 229960004492 suprofen Drugs 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229940111630 tea tree oil Drugs 0.000 description 1
- 239000010677 tea tree oil Substances 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 229960004989 tetracycline hydrochloride Drugs 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- DSNBHJFQCNUKMA-SCKDECHMSA-N thromboxane A2 Chemical compound OC(=O)CCC\C=C/C[C@@H]1[C@@H](/C=C/[C@@H](O)CCCCC)O[C@@H]2O[C@H]1C2 DSNBHJFQCNUKMA-SCKDECHMSA-N 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000006276 transfer reaction Methods 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- MWKJTNBSKNUMFN-UHFFFAOYSA-N trifluoromethyltrimethylsilane Chemical compound C[Si](C)(C)C(F)(F)F MWKJTNBSKNUMFN-UHFFFAOYSA-N 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 229920006163 vinyl copolymer Polymers 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 238000003466 welding Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000002759 woven fabric Substances 0.000 description 1
- 229940102001 zinc bromide Drugs 0.000 description 1
- 239000011592 zinc chloride Substances 0.000 description 1
- 235000005074 zinc chloride Nutrition 0.000 description 1
- 150000003952 β-lactams Chemical class 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/326—Applying electric currents by contact electrodes alternating or intermittent currents for promoting growth of cells, e.g. bone cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0432—Anode and cathode
- A61N1/0436—Material of the electrode
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0432—Anode and cathode
- A61N1/044—Shape of the electrode
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/18—Applying electric currents by contact electrodes
- A61N1/32—Applying electric currents by contact electrodes alternating or intermittent currents
- A61N1/325—Applying electric currents by contact electrodes alternating or intermittent currents for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N1/00—Electrotherapy; Circuits therefor
- A61N1/02—Details
- A61N1/04—Electrodes
- A61N1/0404—Electrodes for external use
- A61N1/0408—Use-related aspects
- A61N1/0428—Specially adapted for iontophoresis, e.g. AC, DC or including drug reservoirs
- A61N1/0448—Drug reservoir
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Radiology & Medical Imaging (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Cell Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Electrotherapy Devices (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50140203P | 2003-09-10 | 2003-09-10 | |
| PCT/IL2004/000821 WO2005023361A2 (en) | 2003-09-10 | 2004-09-09 | Disposable electric bandage |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007504882A true JP2007504882A (ja) | 2007-03-08 |
| JP2007504882A5 JP2007504882A5 (enExample) | 2007-09-20 |
Family
ID=34273043
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006526003A Pending JP2007504882A (ja) | 2003-09-10 | 2004-09-09 | 使い捨て電気包帯 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US7922676B2 (enExample) |
| EP (1) | EP1673139A2 (enExample) |
| JP (1) | JP2007504882A (enExample) |
| WO (1) | WO2005023361A2 (enExample) |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20160118622A (ko) * | 2015-04-02 | 2016-10-12 | 김상유 | 플라즈마 밴드 |
| JP2017505188A (ja) * | 2014-02-04 | 2017-02-16 | ロレアル | 少なくとも２つのコンパートメントを含む電気マスク |
| JP2017537704A (ja) * | 2014-12-05 | 2017-12-21 | エヌエムアール テクノロジー アーエス | イオンを放出する電気化学装置 |
| KR101915697B1 (ko) | 2015-11-23 | 2018-11-06 | 유한실 | 약물전달이 가능한 패치형 전기자극 장치 및 그 제어 방법 |
| JP2021514774A (ja) * | 2018-03-05 | 2021-06-17 | ニューロスティム オーエービー インコーポレイテッド | 非侵襲的な神経刺激 |
| KR20230047275A (ko) * | 2021-09-30 | 2023-04-07 | 단국대학교 천안캠퍼스 산학협력단 | 다기능 상처 치유 패치 |
| JP2023058026A (ja) * | 2021-10-12 | 2023-04-24 | ローバル株式会社 | ウイルスを不活化可能な高濃度亜鉛末塗料 |
| JP2023073133A (ja) * | 2021-11-15 | 2023-05-25 | アイソン株式会社 | 微弱電流発生ヒト適用部品 |
| WO2025159476A1 (ko) * | 2024-01-22 | 2025-07-31 | 계명대학교 산학협력단 | 살균기능이 적용된 욕창 진단 치료기기용 적층형 무선충전 크래들 및 그 이용 방법 |
Families Citing this family (157)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0325129D0 (en) | 2003-10-28 | 2003-12-03 | Smith & Nephew | Apparatus in situ |
| US7662176B2 (en) | 2004-02-19 | 2010-02-16 | Vomaris Innovations, Inc. | Footwear apparatus and methods of manufacture and use |
| US7457667B2 (en) | 2004-02-19 | 2008-11-25 | Silverleaf Medical Products, Inc. | Current producing surface for a wound dressing |
| US8722235B2 (en) | 2004-04-21 | 2014-05-13 | Blue Spark Technologies, Inc. | Thin printable flexible electrochemical cell and method of making the same |
| US20090227930A1 (en) * | 2004-07-15 | 2009-09-10 | Crisp William E | Hygiene materials and absorbents |
| US20100069813A1 (en) * | 2004-07-15 | 2010-03-18 | Crisp William E | Wound dressings |
| US20060015052A1 (en) * | 2004-07-15 | 2006-01-19 | Crisp William E | Wound dressing |
| US7495146B2 (en) * | 2004-07-15 | 2009-02-24 | Vivo Ltd. Partnership | Wound dressing |
| GB2422549A (en) | 2005-02-01 | 2006-08-02 | Wound Solutions Ltd | Flexible electrodes comprising a honey-comb mesh and integrated wound stimulation treatment devices |
| US20060210613A1 (en) * | 2005-03-15 | 2006-09-21 | Carliss Richard D | Therapeutic wound care product |
| US8029927B2 (en) | 2005-03-22 | 2011-10-04 | Blue Spark Technologies, Inc. | Thin printable electrochemical cell utilizing a “picture frame” and methods of making the same |
| US8722233B2 (en) | 2005-05-06 | 2014-05-13 | Blue Spark Technologies, Inc. | RFID antenna-battery assembly and the method to make the same |
| US7182739B2 (en) * | 2005-05-12 | 2007-02-27 | S.C. Johnson & Son, Inc. | Therapy patch |
| US7300409B2 (en) * | 2005-05-12 | 2007-11-27 | S.C. Johnson & Son, Inc. | Therapy patch |
| WO2006133134A2 (en) | 2005-06-03 | 2006-12-14 | Prezacor, Inc. | Compositions comprising elemental metals and uses therefor |
| US20070023291A1 (en) * | 2005-07-15 | 2007-02-01 | Sai Bhavaraju | Metal Trap |
| AU2006287460A1 (en) | 2005-09-07 | 2007-03-15 | Tyco Healthcare Group Lp | Wound dressing with vacuum reservoir |
| CA2620401C (en) | 2005-09-07 | 2016-05-24 | Tyco Healthcare Group Lp | Self contained wound dressing apparatus |
| EP1774987A1 (de) * | 2005-10-12 | 2007-04-18 | Pierenkemper GmbH | Elektrode zur Nerven- und/oder Muskelstimulation und Verfahren zur Nerven- und/oder Muskelstimulation |
| US20070203534A1 (en) * | 2006-02-13 | 2007-08-30 | Robert Tapper | Stimulating galvanic or slow AC current for therapeutic physiological effects |
| US20090099500A1 (en) * | 2006-02-28 | 2009-04-16 | Zvi Nitzan | Multi-function electrode and uses thereof |
| US7779625B2 (en) | 2006-05-11 | 2010-08-24 | Kalypto Medical, Inc. | Device and method for wound therapy |
| WO2009098696A2 (en) * | 2008-02-10 | 2009-08-13 | Empire Bio-Medical Devices Inc. | Device and method for enhanced wound treatment |
| US20080008734A1 (en) * | 2006-07-05 | 2008-01-10 | Perrault James J | Reduction of skin irritation caused by biomedical electrodes |
| US20080027509A1 (en) * | 2006-07-28 | 2008-01-31 | Biofisica Llc | Apparatus and methods for facilitating wound healing and treating skin |
| US20080122582A1 (en) * | 2006-11-29 | 2008-05-29 | Texas Instruments Incorporated | Location Based Portable Device Feature Disabler |
| WO2008094663A2 (en) * | 2007-01-31 | 2008-08-07 | Adam Heller | Electrochemical management of pain |
| EP2115331A1 (de) * | 2007-03-07 | 2009-11-11 | Siemens Aktiengesellschaft | Vorrichtung und verfahren zum herstellen einer dichtung |
| CN101802848A (zh) | 2007-07-18 | 2010-08-11 | 蓝色火花科技有限公司 | 集成电子器件及其制造方法 |
| US20090048504A1 (en) * | 2007-08-17 | 2009-02-19 | Biofisica Inc. | Medical electrode systems and methods |
| US20090048651A1 (en) * | 2007-08-17 | 2009-02-19 | Biofisica Inc. | Medical electrode systems and methods |
| CN101868203B (zh) | 2007-11-21 | 2014-10-22 | 史密夫及内修公开有限公司 | 伤口包敷物 |
| AU2008327660B2 (en) | 2007-11-21 | 2014-02-13 | Smith & Nephew Plc | Wound dressing |
| US8118857B2 (en) * | 2007-11-29 | 2012-02-21 | Boston Scientific Corporation | Medical articles that stimulate endothelial cell migration |
| WO2009085950A2 (en) | 2007-12-19 | 2009-07-09 | Blue Spark Technologies, Inc. | High current thin electrochemical cell and methods of making the same |
| CA2711620A1 (en) | 2008-01-08 | 2009-07-16 | Bluesky Medical Group Inc. | Sustained variable negative pressure wound treatment and method of controlling same |
| WO2009114624A2 (en) | 2008-03-12 | 2009-09-17 | Bluesky Medical Group Inc. | Negative pressure dressing and method of using same |
| KR100950584B1 (ko) * | 2008-04-07 | 2010-04-01 | 주식회사로케트전기 | 전지 일체형 이온토포레시스 패치 |
| WO2009144615A1 (en) * | 2008-05-26 | 2009-12-03 | Koninklijke Philips Electronics N.V. | Moisture control within a multi-electrode patch for monitoring and electrical stimulation of wound healing |
| US8996104B2 (en) * | 2008-06-25 | 2015-03-31 | Fe3 Medical, Inc. | Patches and method for the transdermal delivery of a therapeutically effective amount of iron |
| US8463383B2 (en) * | 2008-08-01 | 2013-06-11 | Ndi Medical, Inc. | Portable assemblies, systems, and methods for providing functional or therapeutic neurostimulation |
| WO2010040357A1 (en) * | 2008-10-06 | 2010-04-15 | Coloplast A/S | Electrical wound dressing having multiple cathodes |
| JP5385582B2 (ja) * | 2008-10-10 | 2014-01-08 | 大学共同利用機関法人自然科学研究機構 | 痛覚神経刺激装置 |
| US20100204752A1 (en) * | 2009-02-10 | 2010-08-12 | Tyco Healthcare Group Lp | Negative Pressure and Electrostimulation Therapy Apparatus |
| US8961492B2 (en) | 2009-02-12 | 2015-02-24 | Incube Labs, Llc | System and method for controlling the iontophoretic delivery of therapeutic agents based on user inhalation |
| US8190252B2 (en) * | 2009-02-12 | 2012-05-29 | Incube Labs, Llc | Iontophoretic system for transdermal delivery of active agents for therapeutic and medicinal purposes |
| WO2010093472A2 (en) * | 2009-02-12 | 2010-08-19 | Incube Labs, Llc | Method and apparatus for oscillatory iontophoretic transdermal delivery of a therapeutic agent |
| US8821945B2 (en) * | 2009-04-25 | 2014-09-02 | Fe3 Medical, Inc. | Method for transdermal iontophoretic delivery of chelated agents |
| US8417330B2 (en) * | 2009-06-26 | 2013-04-09 | Incube Labs, Llc | Corrosion resistant electrodes for iontophoretic transdermal delivery devices and methods of use |
| WO2011044175A2 (en) * | 2009-10-06 | 2011-04-14 | Incube Labs, Llc | Patch and patch assembly for iontophoretic transdermal delivery of active agents for therapeutic and medicinal purposes |
| US8685038B2 (en) | 2009-12-07 | 2014-04-01 | Incube Labs, Llc | Iontophoretic apparatus and method for marking of the skin |
| GB201001631D0 (en) | 2010-02-01 | 2010-03-17 | Eumedic Ltd | Treatment patch electrode for applying electrical impulses to the body of a patient |
| WO2011100376A2 (en) | 2010-02-10 | 2011-08-18 | Incube Labs, Llc | Methods and architecture for power optimization of iontophoretic transdermal drug delivery |
| WO2011163673A2 (en) * | 2010-06-25 | 2011-12-29 | Purdue Research Foundation | System and method for prevention of hypertrophic scars by actuable patch |
| US8795257B2 (en) * | 2010-07-19 | 2014-08-05 | Kci Licensing, Inc. | Systems and methods for electrically detecting the presence of exudate in dressings |
| US9017256B2 (en) | 2010-09-22 | 2015-04-28 | Milieu Institute, Llc | System and method for physiological monitoring |
| US9114258B2 (en) | 2011-01-04 | 2015-08-25 | Kato Medical Systems Llc | Electrokinetic nerve stimulator |
| CN103826696B (zh) | 2011-03-24 | 2017-03-22 | 因卡伯实验室有限责任公司 | 用于治疗剂的两阶段经皮离子电渗递送的系统及方法 |
| WO2012154704A2 (en) | 2011-05-06 | 2012-11-15 | Incube Labs, Llc | System and method for biphasic transdermal iontophoretic delivery of therapeutic agents for the control of addictive cravings |
| WO2013044224A2 (en) | 2011-09-22 | 2013-03-28 | Blue Spark Technologies, Inc. | Cell attachment method |
| EP2780071A4 (en) * | 2011-11-16 | 2015-08-12 | Bodyflow Internat Pty Ltd | METHOD FOR REDUCING HOSPITALIZATION AFTER SURGICAL INTERVENTION |
| EP2804662B1 (en) | 2012-01-16 | 2016-03-30 | Texo Medical ApS | A device for treatment of a wound |
| MX2014011030A (es) | 2012-03-12 | 2015-03-20 | Smith & Nephew | Aparato y metodos de presion reducida. |
| US8765284B2 (en) | 2012-05-21 | 2014-07-01 | Blue Spark Technologies, Inc. | Multi-cell battery |
| US9782082B2 (en) | 2012-11-01 | 2017-10-10 | Blue Spark Technologies, Inc. | Body temperature logging patch |
| US9444078B2 (en) | 2012-11-27 | 2016-09-13 | Blue Spark Technologies, Inc. | Battery cell construction |
| US9295854B2 (en) | 2012-11-28 | 2016-03-29 | Point Source, Inc. | Light and bioelectric therapy pad |
| US10905894B2 (en) | 2013-03-15 | 2021-02-02 | Prezacor, Inc. | Therapeutic bioelectromagnetic fields, pain relief devices, and related methods |
| WO2014178945A1 (en) | 2013-05-02 | 2014-11-06 | Vomaris Innovations, Inc. | Expandable wound dressings |
| US11712557B2 (en) | 2013-05-30 | 2023-08-01 | Neurostim Technologies Llc | Detection and treatment of obstructive sleep apnea |
| US20180154146A1 (en) | 2013-05-30 | 2018-06-07 | NeurostimOAB, Inc. | Non-invasive nerve stimulation |
| US11229789B2 (en) | 2013-05-30 | 2022-01-25 | Neurostim Oab, Inc. | Neuro activator with controller |
| CA2913074C (en) | 2013-05-30 | 2023-09-12 | Graham H. Creasey | Topical neurological stimulation |
| US20180200514A1 (en) * | 2013-05-30 | 2018-07-19 | Neurostim Oab, Inc. | Non-invasive nerve stimulation |
| DE102013011141A1 (de) | 2013-07-03 | 2015-01-08 | Dräger Medical GmbH | Messvorrichtung zur Messung einer Körperfunktion und Verfahren zum Betrieb einer solchen Messvorrichtung |
| KR101369409B1 (ko) * | 2013-07-09 | 2014-03-03 | 김춘기 | 전기 및 미세전류 생성기 |
| US9433785B2 (en) * | 2013-10-21 | 2016-09-06 | Garth Howard Holding | Healing disc, a pain management assembly incorporating the disc, and a method of using the same |
| FR3017054B1 (fr) * | 2014-02-04 | 2016-01-22 | Oreal | Masque electrique comprenant au moins deux compartiments |
| US9496582B1 (en) * | 2014-03-24 | 2016-11-15 | Amazon Technologies, Inc. | Flexible battery |
| PL3191170T3 (pl) * | 2014-09-08 | 2022-06-27 | Fastmeditalia S.R.L. | Plaster zdolny do wytwarzania mikroprądów |
| US9693689B2 (en) | 2014-12-31 | 2017-07-04 | Blue Spark Technologies, Inc. | Body temperature logging patch |
| US11534608B2 (en) | 2015-01-04 | 2022-12-27 | Ist, Llc | Methods and apparatuses for transdermal stimulation of the outer ear |
| US11077301B2 (en) | 2015-02-21 | 2021-08-03 | NeurostimOAB, Inc. | Topical nerve stimulator and sensor for bladder control |
| ES2769811T3 (es) | 2015-04-27 | 2020-06-29 | Smith & Nephew | Aparatos de presión reducida |
| US20180318165A1 (en) | 2015-10-30 | 2018-11-08 | Lorain County Community College Innovation Foundation | Tissue treatment device and method |
| US20190038472A1 (en) * | 2016-02-08 | 2019-02-07 | Vomaris Innovations, Inc. | Composite bioelectric devices and methods of use |
| WO2017153357A1 (en) | 2016-03-07 | 2017-09-14 | Smith & Nephew Plc | Wound treatment apparatuses and methods with negative pressure source integrated into wound dressing |
| UY36936A (es) | 2016-03-31 | 2017-11-30 | Medecell S A | Proceso para establecer un protocolo de electroestimulación, y el respectivo equipo portátil de electroestimulación utilizando el referido protocolo |
| JP7027332B2 (ja) | 2016-04-26 | 2022-03-01 | スミス アンド ネフュー ピーエルシー | 流体浸入阻止構成要素を有する一体化された陰圧源を用いた創傷被覆材及び使用方法 |
| EP3452129B1 (en) | 2016-05-03 | 2022-03-23 | Smith & Nephew plc | Negative pressure wound therapy device activation and control |
| JP6975172B2 (ja) | 2016-05-03 | 2021-12-01 | スミス アンド ネフュー ピーエルシーSmith & Nephew Public Limited Company | 陰圧療法システムにおける陰圧源を駆動するためのシステム及び方法 |
| WO2017191149A1 (en) | 2016-05-03 | 2017-11-09 | Smith & Nephew Plc | Optimizing power transfer to negative pressure sources in negative pressure therapy systems |
| EP3454918A1 (en) | 2016-05-13 | 2019-03-20 | Smith & Nephew PLC | Sensor enabled wound monitoring and therapy apparatus |
| AU2017315129B2 (en) | 2016-08-25 | 2022-10-27 | Smith & Nephew Plc | Absorbent negative pressure wound therapy dressing |
| JP2019528957A (ja) | 2016-09-30 | 2019-10-17 | スミス アンド ネフュー ピーエルシーＳｍｉｔｈ ＆ Ｎｅｐｈｅｗ Ｐｕｂｌｉｃ Ｌｉｍｉｔｅｄ Ｃｏｍｐａｎｙ | 一体化された電子機器を備えた陰圧創傷治療装置及び方法 |
| JP7055795B2 (ja) | 2016-09-30 | 2022-04-18 | スミス アンド ネフュー ピーエルシー | 一体化された電子機器を備えた陰圧創傷治療装置及び方法 |
| WO2019053101A1 (en) | 2017-09-13 | 2019-03-21 | Smith & Nephew Plc | APPARATUS AND METHODS FOR NEGATIVE PRESSURE WOUND TREATMENT WITH INTEGRATED ELECTRONICS |
| US12102508B2 (en) * | 2016-10-21 | 2024-10-01 | Ohio State Innovation Foundation | Antimicrobial wound care dressing |
| CA3046416A1 (en) | 2016-12-12 | 2018-06-21 | Smith & Nephew Plc | Pressure wound therapy status indication via external device |
| US10952907B1 (en) | 2017-02-18 | 2021-03-23 | Tag Off LLC | Acrochordon excising bandage |
| CA3055201A1 (en) | 2017-03-03 | 2018-09-07 | Ohio State Innovation Foundation | Energy generation from fabric electrochemistry |
| AU2018229808B2 (en) | 2017-03-08 | 2024-04-11 | Smith & Nephew Plc | Negative pressure wound therapy device control in presence of fault condition |
| US11324424B2 (en) | 2017-03-09 | 2022-05-10 | Smith & Nephew Plc | Apparatus and method for imaging blood in a target region of tissue |
| EP3592219B1 (en) | 2017-03-09 | 2023-05-10 | Smith & Nephew plc | Device and apparatus of determining skin perfusion pressure |
| WO2018162736A1 (en) | 2017-03-09 | 2018-09-13 | Smith & Nephew Plc | Wound dressing, patch member and method of sensing one or more wound parameters |
| AU2018253383B2 (en) | 2017-04-11 | 2024-05-09 | Smith & Nephew Plc | Component positioning and stress relief for sensor enabled wound dressings |
| CN110612131B (zh) | 2017-05-09 | 2023-05-16 | 史密夫及内修公开有限公司 | 用于负压伤口治疗系统的冗余控件 |
| JP7150750B2 (ja) | 2017-05-15 | 2022-10-11 | スミス アンド ネフュー ピーエルシー | オイラービデオ倍率を使用した陰圧創傷療法システム |
| AU2018269112B2 (en) | 2017-05-15 | 2024-05-02 | Smith & Nephew Plc | Wound analysis device and method |
| CN110753512A (zh) | 2017-06-23 | 2020-02-04 | 史密夫及内修公开有限公司 | 实施传感器的伤口监测或治疗的传感器定位 |
| GB201809007D0 (en) | 2018-06-01 | 2018-07-18 | Smith & Nephew | Restriction of sensor-monitored region for sensor-enabled wound dressings |
| GB201804502D0 (en) | 2018-03-21 | 2018-05-02 | Smith & Nephew | Biocompatible encapsulation and component stress relief for sensor enabled negative pressure wound therapy dressings |
| US10849501B2 (en) | 2017-08-09 | 2020-12-01 | Blue Spark Technologies, Inc. | Body temperature logging patch |
| WO2019030384A2 (en) | 2017-08-10 | 2019-02-14 | Smith & Nephew Plc | SENSOR POSITIONING FOR MONITORING OR TREATING SENSOR ACTIVATED WOUNDS |
| JP7653254B2 (ja) | 2017-09-10 | 2025-03-28 | スミス アンド ネフュー ピーエルシー | 封入を検査するためのシステムおよび方法、ならびにセンサを装備した創傷被覆材内の構成要素 |
| GB201718870D0 (en) | 2017-11-15 | 2017-12-27 | Smith & Nephew Inc | Sensor enabled wound therapy dressings and systems |
| GB201804971D0 (en) | 2018-03-28 | 2018-05-09 | Smith & Nephew | Electrostatic discharge protection for sensors in wound therapy |
| GB201718070D0 (en) | 2017-11-01 | 2017-12-13 | Smith & Nephew | Negative pressure wound treatment apparatuses and methods with integrated electronics |
| GB201718859D0 (en) | 2017-11-15 | 2017-12-27 | Smith & Nephew | Sensor positioning for sensor enabled wound therapy dressings and systems |
| EP3687380A1 (en) | 2017-09-27 | 2020-08-05 | Smith & Nephew plc | Ph sensing for sensor enabled negative pressure wound monitoring and therapy apparatuses |
| US11839464B2 (en) | 2017-09-28 | 2023-12-12 | Smith & Nephew, Plc | Neurostimulation and monitoring using sensor enabled wound monitoring and therapy apparatus |
| US11246765B2 (en) | 2017-10-25 | 2022-02-15 | Neurostim Solutions LLC | Smart diaper system |
| US11497653B2 (en) | 2017-11-01 | 2022-11-15 | Smith & Nephew Plc | Negative pressure wound treatment apparatuses and methods with integrated electronics |
| GB201718054D0 (en) | 2017-11-01 | 2017-12-13 | Smith & Nephew | Sterilization of integrated negative pressure wound treatment apparatuses and sterilization methods |
| GB201718072D0 (en) | 2017-11-01 | 2017-12-13 | Smith & Nephew | Negative pressure wound treatment apparatuses and methods with integrated electronics |
| US11986645B2 (en) | 2017-11-07 | 2024-05-21 | Neurostim Technologies Llc | Restless legs syndrome treatment system |
| CA3082390C (en) | 2017-11-07 | 2023-01-31 | Neurostim Oab, Inc. | Non-invasive nerve activator with adaptive circuit |
| US11305113B2 (en) | 2017-11-11 | 2022-04-19 | Neurostim Solutions LLC | Nocturia reduction system |
| WO2019096828A1 (en) | 2017-11-15 | 2019-05-23 | Smith & Nephew Plc | Integrated sensor enabled wound monitoring and/or therapy dressings and systems |
| GB201814011D0 (en) | 2018-08-29 | 2018-10-10 | Smith & Nephew | Componet positioning and encapsulation for sensor enabled wound dressings |
| US11944418B2 (en) | 2018-09-12 | 2024-04-02 | Smith & Nephew Plc | Device, apparatus and method of determining skin perfusion pressure |
| USD898925S1 (en) | 2018-09-13 | 2020-10-13 | Smith & Nephew Plc | Medical dressing |
| WO2020064937A1 (en) | 2018-09-28 | 2020-04-02 | T.J.Smith And Nephew,Limited | Optical fibers for optically sensing through wound dressings |
| GB201816838D0 (en) | 2018-10-16 | 2018-11-28 | Smith & Nephew | Systems and method for applying biocompatible encapsulation to sensor enabled wound monitoring and therapy dressings |
| GB201820927D0 (en) | 2018-12-21 | 2019-02-06 | Smith & Nephew | Wound therapy systems and methods with supercapacitors |
| US20220118253A1 (en) * | 2019-01-18 | 2022-04-21 | Ist, Llc | Systems and methods for craniocervical and auricular neuromodulation |
| WO2020150737A1 (en) | 2019-01-18 | 2020-07-23 | Ist, Llc | Methods and devices for modulation of integrated neural networks to influence composite sensory processes |
| WO2020157103A1 (en) | 2019-01-30 | 2020-08-06 | Smith & Nephew Plc | Sensor integrated dressings and systems |
| EP4570219A1 (en) | 2019-03-18 | 2025-06-18 | Smith & Nephew plc | Design rules for sensor integrated substrates |
| EP3941346A1 (en) | 2019-03-19 | 2022-01-26 | Smith & Nephew plc | Systems and methods for measuring tissue impedance |
| GB201903774D0 (en) | 2019-03-20 | 2019-05-01 | Smith & Nephew | Negative pressure wound treatment apparatuses and methods with integrated electronics |
| US11478638B2 (en) | 2019-03-22 | 2022-10-25 | Neurostim Technologies Llc | Detection and treatment of obstructive sleep apnea |
| US11305110B2 (en) | 2019-03-22 | 2022-04-19 | Neurostim Technologies Llc | Detection and treatment of obstructive sleep apnea |
| GB201907716D0 (en) | 2019-05-31 | 2019-07-17 | Smith & Nephew | Systems and methods for extending operational time of negative pressure wound treatment apparatuses |
| EP3990100A4 (en) | 2019-06-26 | 2023-07-19 | Neurostim Technologies LLC | NON-INVASIVE NERVE ACTIVATOR WITH ADAPTIVE CIRCUIT |
| GB201914443D0 (en) | 2019-10-07 | 2019-11-20 | Smith & Nephew | Sensor enabled negative pressure wound monitoring apparatus with different impedances inks |
| CA3152451A1 (en) | 2019-12-16 | 2021-06-24 | Michael Bernard Druke | Non-invasive nerve activator with boosted charge delivery |
| GB201918856D0 (en) | 2019-12-19 | 2020-02-05 | Smith & Nephew | Sensor integrated dressings and systems |
| US20210267625A1 (en) | 2020-02-28 | 2021-09-02 | Tag Off LLC | Skin Growth Excision Apparatus |
| GB202003203D0 (en) | 2020-03-05 | 2020-04-22 | Smith & Nephew | Sensor integrated dressings and systems |
| WO2021185423A1 (en) * | 2020-03-17 | 2021-09-23 | Lempré Aps | Patch for electrical stimulation of skin tissue |
| GB2609367B (en) | 2020-04-21 | 2024-09-25 | Smith & Nephew | Wound treatment management using augmented reality overlay |
| GB202007391D0 (en) | 2020-05-19 | 2020-07-01 | Smith & Nephew | Patient protection from unsafe electric current in sensor integrated dressings and systems |
| PL434068A1 (pl) * | 2020-05-25 | 2021-11-29 | Prevlly Spółka Z Ograniczoną Odpowiedzialnością | Opatrunek warstwowy elektrostymulujący oraz sposób elektrostymulacji |
| CN112843465B (zh) * | 2020-12-31 | 2023-09-19 | 北京理工大学 | 便携式电愈贴及其制备方法 |
| US12329669B2 (en) * | 2021-10-27 | 2025-06-17 | Stetrix, Inc. | Perianal support device with flexible side supports |
| CN119184963B (zh) * | 2024-08-16 | 2025-03-25 | 浙江大学 | 一种创面愈合用药物电控释水凝胶贴片 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003035166A2 (en) * | 2001-10-24 | 2003-05-01 | Power Paper Ltd. | Dermal patch |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3914662A1 (de) * | 1989-05-03 | 1990-11-08 | Alt Eckhard | Vorrichtung zum uebertragen elektrischer signale zwischen einem implantierbaren medizinischen geraet und elektrisch erregbarem menschlichen gewebe |
| US5652043A (en) * | 1995-12-20 | 1997-07-29 | Baruch Levanon | Flexible thin layer open electrochemical cell |
| AU3404097A (en) * | 1996-06-19 | 1998-01-07 | Becton Dickinson & Company | Iontophoretic delivery of cell adhesion inhibitors |
| US6185453B1 (en) * | 1996-06-19 | 2001-02-06 | Dupont Pharmaceuticals Company | Iontophoretic delivery of integrin inhibitors |
| US6246904B1 (en) | 1996-12-17 | 2001-06-12 | Alza Corporation | Electrotransport drug delivery reservoirs containing inert fillers |
| US5974344A (en) | 1998-03-02 | 1999-10-26 | Shoemaker, Ii; Charles | Wound care electrode |
| EP1292628B1 (en) * | 2000-06-15 | 2010-06-09 | First Water Limited | Process for the manufacture of hydrogel compositions and hydrogel compositions manufactured thereby |
| US6560483B1 (en) | 2000-10-18 | 2003-05-06 | Minnesota High-Tech Resources, Llc | Iontophoretic delivery patch |
-
2004
- 2004-09-09 EP EP04770492A patent/EP1673139A2/en not_active Withdrawn
- 2004-09-09 US US10/936,540 patent/US7922676B2/en not_active Expired - Fee Related
- 2004-09-09 JP JP2006526003A patent/JP2007504882A/ja active Pending
- 2004-09-09 WO PCT/IL2004/000821 patent/WO2005023361A2/en not_active Ceased
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2003035166A2 (en) * | 2001-10-24 | 2003-05-01 | Power Paper Ltd. | Dermal patch |
Cited By (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017505188A (ja) * | 2014-02-04 | 2017-02-16 | ロレアル | 少なくとも２つのコンパートメントを含む電気マスク |
| JP2017537704A (ja) * | 2014-12-05 | 2017-12-21 | エヌエムアール テクノロジー アーエス | イオンを放出する電気化学装置 |
| KR101672824B1 (ko) | 2015-04-02 | 2016-11-04 | 서재화 | 플라즈마 밴드 |
| KR20160118622A (ko) * | 2015-04-02 | 2016-10-12 | 김상유 | 플라즈마 밴드 |
| KR101915697B1 (ko) | 2015-11-23 | 2018-11-06 | 유한실 | 약물전달이 가능한 패치형 전기자극 장치 및 그 제어 방법 |
| JP7434163B2 (ja) | 2018-03-05 | 2024-02-20 | ニューロスティム オーエービー インコーポレイテッド | 非侵襲的な神経刺激 |
| JP2021514774A (ja) * | 2018-03-05 | 2021-06-17 | ニューロスティム オーエービー インコーポレイテッド | 非侵襲的な神経刺激 |
| KR20230047275A (ko) * | 2021-09-30 | 2023-04-07 | 단국대학교 천안캠퍼스 산학협력단 | 다기능 상처 치유 패치 |
| KR102731280B1 (ko) * | 2021-09-30 | 2024-11-18 | 단국대학교 천안캠퍼스 산학협력단 | 다기능 상처 치유 패치 |
| JP7287730B2 (ja) | 2021-10-12 | 2023-06-06 | ローバル株式会社 | ウイルスを不活化可能な高濃度亜鉛末塗料 |
| JP2023058026A (ja) * | 2021-10-12 | 2023-04-24 | ローバル株式会社 | ウイルスを不活化可能な高濃度亜鉛末塗料 |
| JP2023073133A (ja) * | 2021-11-15 | 2023-05-25 | アイソン株式会社 | 微弱電流発生ヒト適用部品 |
| WO2025159476A1 (ko) * | 2024-01-22 | 2025-07-31 | 계명대학교 산학협력단 | 살균기능이 적용된 욕창 진단 치료기기용 적층형 무선충전 크래들 및 그 이용 방법 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20050085751A1 (en) | 2005-04-21 |
| US7922676B2 (en) | 2011-04-12 |
| WO2005023361A3 (en) | 2005-04-21 |
| EP1673139A2 (en) | 2006-06-28 |
| WO2005023361A2 (en) | 2005-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007504882A (ja) | 使い捨て電気包帯 | |
| RU2372113C2 (ru) | Способ, устройство и набор для лечения онихомикоза с использованием электрокинетического переноса веществ | |
| KR101208934B1 (ko) | 사람 또는 동물의 차단막 치료용 기구 | |
| CN1826153B (zh) | 用原电池产生的电流治疗痤疮和红斑痤疮的方法 | |
| US7340297B2 (en) | Kit, device and method for controlled delivery of oxidizing agent into the skin | |
| JP2005506158A5 (enExample) | ||
| CN1606461A (zh) | 用于将活性物质受控地输送到皮肤中的装置和方法 | |
| JP2006526454A5 (enExample) | ||
| JPWO1995035132A1 (ja) | イオントフォレーシス用電極及びそれを用いたデバイス | |
| CN1607970A (zh) | 皮肤贴片 | |
| EP1984073A1 (en) | Power source electrode treatment device | |
| US20100069813A1 (en) | Wound dressings | |
| CN104147694A (zh) | 处理人或动物屏障膜的装置 | |
| JPH0852224A (ja) | イオントフォレーシス用デバイス | |
| JPH08173554A (ja) | 皮接治療具 | |
| JP2015503425A (ja) | 創傷の治療のためのデバイス | |
| WO2001013988A1 (en) | Devices and methods for the generation of voltage potential | |
| JPH02241464A (ja) | イオントフォレーゼ用デバイス | |
| Anisimov et al. | Development of a portable device for iontophoresis | |
| HK1102401A (en) | Method, apparatus, and kit for onychomycosis treatment using electrokinetic transport of substances | |
| HK1092744A (en) | Device for treatment of human or animal barrier membranes | |
| HK1092398A (en) | Methods of treating pores on the skin with electricity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070718 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20070718 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100202 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100706 |